However, the very same agonistic anti-CD137 antibodies that enhance anti-tumor immunity have been shown to quench autoimmunity and to ameliorate autoimmune diseases, including experimental autoimmune encephalomyelitis and type 1 diabetes [8], [9], [10], [50], [51]. Here, TNFRSF9 is linked to autoimmune disease.